NDAIMPLANTATIONIMPLANTPriority Review
Approved
May 2016
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
3/8 — Basic
Priority Review
PROBUPHINE (buprenorphine hydrochloride) by Teva is naloxone. First approved in 2016.
Drug data last refreshed 9h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PROBUPHINE is a subdermal implant containing buprenorphine hydrochloride for the treatment of opioid use disorder. Buprenorphine acts as a partial agonist at the mu-opioid receptor and antagonist at the kappa-opioid receptor, providing sustained opioid replacement therapy over an extended period. The implant delivery mechanism offers improved medication adherence compared to daily oral formulations.
Peak
Peak lifecycle stage suggests established sales infrastructure but heightened competitive pressure (30% competitive intensity) indicating active brand defense and market positioning initiatives.
Mechanism of Action
naloxone. Buprenorphine is a partial agonist at the mu-opioid receptor and an antagonist at the kappa-opioid receptor. Naloxone is an opioid antagonist and produces opioid withdrawal signs and symptoms in individuals physically dependent on full opioid agonists when administered parenterally.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Probuphine Innovations for Clinical Effectiveness (PRINCE)
Started Sep 2016
15 enrolled
Opioid Dependence
Career Relevance
PROBUPHINE operates in peak lifecycle with moderate competitive pressure, creating career opportunities focused on market defense, reimbursement strategy, and specialized sales execution. This product offers exposure to addiction medicine and long-acting delivery platforms, appealing to professionals targeting underserved patient populations and innovative formulation experience.
Brand Manager
Worked on PROBUPHINE at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.